Evaxion Biotech A/S
| NASDAQ: EVAX | - / - / - |
| 1.13 | +0.0550 | +5.12% | Vol 61.37K | 1Y Perf -64.52% |
| Mar 31st, 2023 16:00 DELAYED |
| BID | 1.01 | ASK | 1.21 | ||
| Open | 1.11 | Previous Close | 1.13 | ||
| Pre-Market | - | After-Market | 1.14 | ||
| - - | 0.01 0.88% |
| Target Price | 13.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 1.05K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 8.08 | Earnings Rating | — | |
| Market Cap | 29.86M | Earnings Date | 4th Apr 2023 | |
| Alpha | -0.05 | Standard Deviation | 0.23 | |
| Beta | -0.13 |
Today's Price Range 1.061.16 | 52W Range 0.92003.52 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -8.87% | ||
| 1 Month | -22.87% | ||
| 3 Months | -36.34% | ||
| 6 Months | -57.03% | ||
| 1 Year | -64.52% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | 100.46 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -95.68 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -168.27 | |||
Return on invested Capital Q | -35.03 | |||
Return on invested Capital Y | -112.88 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.50 | ||||
| 3.81 | ||||
| - | ||||
| - | ||||
| -2.80 | ||||
| -1.03 | ||||
| -0.59 | ||||
| -2.72 | ||||
| 23.32M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.00 | ||||
| 6.50 | ||||
| 0.32 | ||||
| 0.48 | ||||
| -101.30 | ||||
| Leverage Ratio | -5.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | -0.34 | -0.24 | 29.41 |
| Q02 2022 | -0.33 | -0.20 | 39.39 |
| Q01 2022 | -0.35 | -0.25 | 28.57 |
| Q04 2021 | -0.30 | -0.39 | -30.00 |
| Q03 2021 | -0.35 | -0.27 | 22.86 |
| Q02 2021 | -0.29 | -0.36 | -24.14 |
| Q01 2021 | -0.33 | -0.23 | 30.30 |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 4th Apr 2023 |
| Estimated EPS Next Report | -0.28 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 61.37K |
| Shares Outstanding | 26.42K |
| Shares Float | 23.83M |
| Trades Count | 253 |
| Dollar Volume | 67.38K |
| Avg. Volume | 259.14K |
| Avg. Weekly Volume | 66.91K |
| Avg. Monthly Volume | 113.28K |
| Avg. Quarterly Volume | 597.23K |
Evaxion Biotech A/S (NASDAQ: EVAX) stock closed at 1.13 per share at the end of the most recent trading day (a 5.12% change compared to the prior day closing price) with a volume of 61.37K shares and market capitalization of 29.86M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the industry, sector and employs 0 people. Evaxion Biotech A/S CEO is .
The one-year performance of Evaxion Biotech A/S stock is -64.52%, while year-to-date (YTD) performance is -36.34%. EVAX stock has a five-year performance of %. Its 52-week range is between 0.92 and 3.5199, which gives EVAX stock a 52-week price range ratio of 8.08%
Evaxion Biotech A/S currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 3.81, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -95.68%, a ROC of -168.27% and a ROE of 100.46%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Evaxion Biotech A/S, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Evaxion Biotech A/S’s next earnings report date is 04th Apr 2023.
The consensus rating of Wall Street analysts for Evaxion Biotech A/S is Strong Buy (1), with a target price of $13, which is +1 050.44% compared to the current price. The earnings rating for Evaxion Biotech A/S stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Evaxion Biotech A/S has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Evaxion Biotech A/S has a Neutral technical analysis rating based on Technical Indicators (ADX : 42.44, ATR14 : 0.13, CCI20 : 2.31, Chaikin Money Flow : -0.07, MACD : -0.08, Money Flow Index : 57.29, ROC : 4.63, RSI : 43.83, STOCH (14,3) : 46.67, STOCH RSI : 0.61, UO : 55.58, Williams %R : -53.33), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Evaxion Biotech A/S in the last 12-months were:
